Technetium Tc-99m depreotide injection receives "approvable" letter Dec. 17 for imaging of suspected malignant lung tumors. FDA requests clarification and additional analysis of safety and efficacy data, as well as additional chemistry assays as part of Phase IV commitments. The product had priority review status and the "approvable" letter was sent six months after the NDA submission, Londonderry, N.H.-based Diatide reports
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth